Cerus Corp - Company Profile

Powered by

All the data and insights you need on Cerus Corp in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Cerus Corp Strategy Report

  • Understand Cerus Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Cerus Corp: Overview

Select Item

Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce intercept fibrinogen complex (IFC), and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.

 Gain a 360-degree view of Cerus Corp and make more informed decisions for your business Gain a 360-degree view of Cerus Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 2550 Stanwell Drive, Concord, California, 94520
Website www.cerus.com
Telephone 1 925 2886000
No of Employees 309
Industry Medical Equipment
Ticker Symbol & Exchange CERS (NASD)
Revenue (2022) $188.3M 18.1% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 21.3% (2022 vs 2021)
Market Cap* $297.3M
Net Profit Margin (2022) XYZ 33.4% (2022 vs 2021)
* As of and is in US$
View Cerus Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Cerus Corp premium industry data and analytics

20+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

5

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Cerus Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
- -
UVA Illumination Devices Intercept
Intercept Blood System for Platelets and Plasma
XYZ
XYZ
XYZ
Understand Cerus Corp portfolio and identify potential areas for collaboration Understand Cerus Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In November, the company entered into an agreement with Bloodbuy to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex through the Bloodbuy online marketplace.
2022 Regulatory Approval In November, the company received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System with seven-day storage.
2022 Contracts/Agreements In May, the company entered into an agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Cerus Corp Grifols SA Octapharma AG Kedrion Biopharma Inc MacoPharma International Gmbh
Headquarters United States of America Spain Switzerland United States of America Germany
City Concord Barcelona Lachen Fort Lee Langen
State/Province California Barcelona Schwyz New Jersey Hessen
No. of Employees 309 23,245 11,573 - -
Entity Type Public Public Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Daniel N. Swisher Jr. Chairman Executive Board 2013 60
William M. Greenman President; Director; Chief Executive Officer Executive Board 2011 56
Kevin D. Green Vice President - Finance; Chief Financial Officer Senior Management 2013 51
Vivek K. Jayaraman Chief Operating Officer Senior Management 2020 48
Chrystal N. Menard General Counsel; Chief Legal Officer Senior Management 2012 52
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Cerus Corp key executives to enhance your sales strategy Gain insight into Cerus Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward